Disc Medicine
IRON
49 hedge funds and large institutions have $347M invested in Disc Medicine in 2021 Q1 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
343% more call options, than puts
Call options by funds: $5.2M | Put options by funds: $1.17M
60.11% more ownership
Funds ownership: 0% → 60.11% (+60%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$86.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.5M |
| 3 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$36.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.5M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$22M |
Top Sellers
IRON Hedge Fund Activity: Q1 2021 in Review
49 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Disc Medicine (IRON) for Q1 2021, worth a combined $347M.
Buyers outnumbered sellers: 49 funds opened new IRON positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $86.6M.
- 49 institutional investors held Disc Medicine (IRON) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $347M of Disc Medicine stock for Q1 2021.
- 49 funds opened new Disc Medicine positions in Q1 2021 and 0 closed out, a net change of +49 holders.
- The largest Disc Medicine buyer in Q1 2021 was OrbiMed, an estimated $86.6M added.
Based on aggregated 13F filings for Q1 2021.